JP2023518268A5 - - Google Patents

Info

Publication number
JP2023518268A5
JP2023518268A5 JP2022556250A JP2022556250A JP2023518268A5 JP 2023518268 A5 JP2023518268 A5 JP 2023518268A5 JP 2022556250 A JP2022556250 A JP 2022556250A JP 2022556250 A JP2022556250 A JP 2022556250A JP 2023518268 A5 JP2023518268 A5 JP 2023518268A5
Authority
JP
Japan
Prior art keywords
dsrna
nucleotides
chain
antisense
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518268A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022748 external-priority patent/WO2021188661A1/en
Publication of JP2023518268A publication Critical patent/JP2023518268A/ja
Publication of JP2023518268A5 publication Critical patent/JP2023518268A5/ja
Pending legal-status Critical Current

Links

JP2022556250A 2020-03-18 2021-03-17 Snca調節のためのオリゴヌクレオチド Pending JP2023518268A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062991406P 2020-03-18 2020-03-18
US62/991,406 2020-03-18
US202063071115P 2020-08-27 2020-08-27
US63/071,115 2020-08-27
PCT/US2021/022748 WO2021188661A1 (en) 2020-03-18 2021-03-17 Oligonucleotides for snca modulation

Publications (2)

Publication Number Publication Date
JP2023518268A JP2023518268A (ja) 2023-04-28
JP2023518268A5 true JP2023518268A5 (cg-RX-API-DMAC7.html) 2024-03-27

Family

ID=77772170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556250A Pending JP2023518268A (ja) 2020-03-18 2021-03-17 Snca調節のためのオリゴヌクレオチド

Country Status (10)

Country Link
US (2) US20210363524A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121538A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023518268A (cg-RX-API-DMAC7.html)
KR (1) KR20230002327A (cg-RX-API-DMAC7.html)
CN (1) CN115777021A (cg-RX-API-DMAC7.html)
AU (1) AU2021238326A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018475A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171757A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011536A (cg-RX-API-DMAC7.html)
WO (1) WO2021188661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230416735A1 (en) * 2022-04-14 2023-12-28 University Of Massachusetts Oligonucleotides for atn1 modulation
US20240052344A1 (en) * 2022-05-04 2024-02-15 University Of Massachusetts Oligonucleotides for pms1 modulation
JP2025531512A (ja) * 2022-09-29 2025-09-19 アタランタ セラピューティクス,インコーポレーテッド アルファシヌクレイン核酸を標的化するsiRNA組成物及び方法
WO2024166019A1 (en) * 2023-02-08 2024-08-15 Biorchestra Co., Ltd. Sirna targeting alpha-synuclein and uses thereof
CN122374456A (zh) * 2023-10-20 2026-07-10 斯帕克医疗有限公司 靶向 α 突触核蛋白表达的抑制性核酸
TW202523678A (zh) * 2023-12-14 2025-06-16 國立臺灣大學 CRISPRI標靶α-突觸核蛋白
TW202529779A (zh) * 2024-01-30 2025-08-01 大陸商上海舶望製藥有限公司 用於抑制突觸核蛋白α(SNCA)基因表達的組合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005045034A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
WO2008109509A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting snca gene expression and uses thereof
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US20100275274A1 (en) * 2009-04-28 2010-10-28 National Yang-Ming University Mouse model for depression, schizophrenia and alzheimer's disease
WO2010141511A2 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2012027713A2 (en) * 2010-08-26 2012-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of snca
EP3521451A1 (en) * 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP3929293A3 (en) * 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
RS60762B1 (sr) * 2015-04-03 2020-10-30 Univ Massachusetts Oligonukleotidna jedinjenja za ciljane irnk hantingtina
WO2017132669A1 (en) * 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
TW202509215A (zh) * 2018-08-03 2025-03-01 美商健臻公司 針對α-突觸核蛋白的變體RNAi
BR112021002440A2 (pt) * 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
JP2025531512A (ja) * 2022-09-29 2025-09-19 アタランタ セラピューティクス,インコーポレーテッド アルファシヌクレイン核酸を標的化するsiRNA組成物及び方法

Similar Documents

Publication Publication Date Title
JP2023522701A5 (cg-RX-API-DMAC7.html)
JP2023518439A5 (cg-RX-API-DMAC7.html)
JP2022528487A5 (cg-RX-API-DMAC7.html)
JP2023550485A5 (cg-RX-API-DMAC7.html)
JP7554488B2 (ja) 血液脳関門通過型ヘテロ2本鎖核酸
JP2022525208A5 (cg-RX-API-DMAC7.html)
JP7129702B2 (ja) オーバーハングを有する二本鎖核酸複合体
JP6638923B2 (ja) キメラ2重鎖核酸
JP2021533804A5 (cg-RX-API-DMAC7.html)
JP2018516091A5 (cg-RX-API-DMAC7.html)
JP2021533762A5 (cg-RX-API-DMAC7.html)
JP2019503394A5 (cg-RX-API-DMAC7.html)
WO2016115490A1 (en) Compounds and methods for modulation of dux4
TW202246502A (zh) 抑制中樞神經系統中的基因表現之組成物及方法
JPWO2019181946A1 (ja) 毒性が軽減した核酸
JP2024523466A5 (cg-RX-API-DMAC7.html)
JP2026514403A (ja) オリゴヌクレオチド送達担体およびその使用方法
WO2021157730A1 (ja) 核酸医薬とその使用
EP4426839A1 (en) Lipid conjugation for targeting astrocytes of the central nervous system
EP4426432A1 (en) Lipid conjugation for targeting oligodendrocytes of the central nervous system
US20240287512A1 (en) Lipid conjugation for targeting neurons of the central nervous system
JP6934695B2 (ja) 核酸医薬とその使用
AU2016217825B2 (en) Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
CN119630791A (zh) 用于抑制snca表达的组合物和方法
CN117597444A (zh) 用于靶向中枢神经系统的神经元的脂质缀合